These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18804131)

  • 21. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
    Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
    Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.
    Kistner O; Howard MK; Spruth M; Wodal W; Brühl P; Gerencer M; Crowe BA; Savidis-Dacho H; Livey I; Reiter M; Mayerhofer I; Tauer C; Grillberger L; Mundt W; Falkner FG; Barrett PN
    Vaccine; 2007 Aug; 25(32):6028-36. PubMed ID: 17614165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
    Crevar CJ; Carter DM; Lee KY; Ross TM
    Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge.
    Liu G; Zhang F; Shi J; Tian G; Chen H; Yu K; Meng Q
    Vaccine; 2013 Nov; 31(46):5398-404. PubMed ID: 24055355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.
    Park SJ; Si YJ; Kim J; Song MS; Kim SM; Kim EH; Kwon HI; Kim YI; Lee OJ; Shin OS; Kim CJ; Shin EC; Choi YK
    Virology; 2016 Nov; 498():36-43. PubMed ID: 27543757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.
    Prabakaran M; Leyrer S; He F; Auer S; Kumar SR; Kindsmueller K; Mytle N; Schneider J; Lockhart S; Kwang J
    PLoS One; 2014; 9(9):e107316. PubMed ID: 25229722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
    Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
    J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.
    Cao W; Kim JH; Reber AJ; Hoelscher M; Belser JA; Lu X; Katz JM; Gangappa S; Plante M; Burt DS; Sambhara S
    Vaccine; 2017 Jun; 35(25):3318-3325. PubMed ID: 28499553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
    Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
    Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgG antibodies mediate protective immunity of inactivated vaccine for highly pathogenic H5N1 influenza viruses in ferrets.
    Shin JS; Kim HS; Cho SH; Seo SH
    Viral Immunol; 2010 Jun; 23(3):321-7. PubMed ID: 20565295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.